DOI: 10.1055/s-00023610

Drug Research

References

Komoroski B, Vachharajani N, Feng Y et al.
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Clin Pharmacol Ther 2009;
85: 513-519

Download Bibliographical Data

Search in:
Access: